|
[1]
|
Podolsky, D.K. (2002) Inflammatory bowel disease. New England Journal of Medicine, 347, 417-429.
http://dx.doi.org/10.1056/NEJMra020831
|
|
[2]
|
Markowitz, J., Grancher, K., Kohn, N. and Daum, F. (2002) Immunomodulatory therapy for pediatric inflammatory bowel disease: Changing patterns of use, 1990-2000. American Journal of Gastroenterology, 97, 928-932.
|
|
[3]
|
Boer, N.K.H., Mulder, C.J.J. and van Bodegraven, A.A. (2005) Myelotoxicity and hepatotoxicity during azathioprine therapy. Netherlands Journal of Medicine, 63, 444-446.
|
|
[4]
|
Pearson, D.C., May, G.R., Fick, G.H. and Sutherland, L.R. (1995) Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Annals of Internal Medicine, 123, 132-142.
http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00009
|
|
[5]
|
Fraser, A.G., Orchard, T.R. and Jewell, D.P. (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review. Gut, 50, 485-489.
http://dx.doi.org/10.1136/gut.50.4.485
|
|
[6]
|
Lowry, P.W., Franklin, C.L., Weaver, A.L., et al. (2001) Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut, 49, 665-670.
http://dx.doi.org/10.1136/gut.49.5.665
|
|
[7]
|
Gisbert, J.P., González-Lama, Y. and Maté, J. (2007) Thiopurine-induced liver injury in patients with inflamematory bowel disease: A systematic review. American Journal of Gastroenterology, 102, 1518-1527.
http://dx.doi.org/10.1111/j.1572-0241.2007.01187.x
|
|
[8]
|
Macdonald, A. (2006) Omega-3 fatty acids as adjunctive therapy in Crohns disease. Gastroenterology Nursing, 29, 295-301.
http://dx.doi.org/10.1097/00001610-200607000-00005
|
|
[9]
|
Cuffari, C., Dassopoulos, T., Turnbough, L., Thompson, R.E. and Bayless, T.M. (2004) Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clinical Gastroenterology and Hepatology, 2, 410-417.
http://dx.doi.org/10.1016/S1542-3565(04)00127-2
|
|
[10]
|
Kiefer, K. and El-Matary, W. (2009) 6 mercaptopurine as an alternative to azathioprine in azathioprine-induced hepatoxicity. Inflammatory Bowel Diseases, 15, 318-319.
http://dx.doi.org/10.1002/ibd.20603
|
|
[11]
|
Boson, W.L., Romano-Silva, M.A., Correa, H., Falcao, R.P., Teixeira-Vidigal, P.V. and De Marco, L. (2003) Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics Journal, 3, 178-182. http://dx.doi.org/10.1038/sj.tpj.6500175
|
|
[12]
|
Dubinsky, M.C., Lamothe, S. and Yang, H.Y. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 118, 705-713.
http://dx.doi.org/10.1016/S0016-5085(00)70140-5
|
|
[13]
|
Dubinsky, M.C., Yang, H. and Hassard, P.V. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology, 122, 904-915.
http://dx.doi.org/10.1053/gast.2002.32420
|
|
[14]
|
Hosni-Ahmed, A., Barnes, J.D., Wan, J. and Jones, T.S. (2011) Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. PLoS One, 6, e29163.
http://dx.doi.org/10.1371/journal.pone.0029163
|
|
[15]
|
Coulthard, S. and Hogarth, L. (2005) The thiopurines: An update. Investigational New Drugs, 23, 523-532.
http://dx.doi.org/10.1007/s10637-005-4020-8
|
|
[16]
|
Gastal, G.R., Moreira, S., Noble, C.F., Ferreira, L.E., Franca, P.H. and Pinho, M. (2012) Toxicity of azathioprine: Why and when? Analysis of the prevalence of polymorphism in Joinville, SC, Brazil. Arquivos de Gastroenterologia, 49, 130-134.
http://dx.doi.org/10.1590/S0004-28032012000200007
|